[ad_1] July 11, 2018 The results of the Phase 1b clinical trials published in JAMA Oncology are promising for the badociation of tucatinib (formerly ONT-380) with T-DM1 against HER2-positive bad cancer heavily …
Read More »Tucatinib clinical trial results with T-DM1 are promising in the treatment of HER2 + breast cancer
